A three-arm, randomized, double-blind, placebo controlled, multicenter, phase II study to evaluate the efficacy of Vigantol oil as add-on therapy in subjects with Relapsing-Remitting Multiple Sclerosis receiving treatment with 44 μg tiw of Rebif SOLAR Supplementation of VigantOL Oil versus Placebo as Add-on in Patients with Relapsing-Remitting MS receiving Rebif treatment.

Trial Profile

A three-arm, randomized, double-blind, placebo controlled, multicenter, phase II study to evaluate the efficacy of Vigantol oil as add-on therapy in subjects with Relapsing-Remitting Multiple Sclerosis receiving treatment with 44 μg tiw of Rebif SOLAR Supplementation of VigantOL Oil versus Placebo as Add-on in Patients with Relapsing-Remitting MS receiving Rebif treatment.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2016

At a glance

  • Drugs Interferon beta-1a (Primary) ; Colecalciferol
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms SOLAR
  • Sponsors Merck KGaA; Merck Serono
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 12 Sep 2016 Data from this trial will be presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), according to a Merck & Co media release.
    • 03 Jun 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top